Bladder Cancer Accelerated Approvals: Merck’s Keytruda and Genentech’s Tecentriq Each May Have One Last Lifeline

 
• By Sarah Karlin-Smith
image of hand "lifeline"
Keytruda and Tecentriq's first-line bladder cancer indications may be on their last lifeline. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers